These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
272 related articles for article (PubMed ID: 9033637)
1. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637 [TBL] [Abstract][Full Text] [Related]
2. Determinants of CPT-11 and SN-38 activities in human lung cancer cells. van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129 [TBL] [Abstract][Full Text] [Related]
3. Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity. Hennebelle I; Terret C; Chatelut E; Bugat R; Canal P; Guichard S Anticancer Drugs; 2000 Jul; 11(6):465-70. PubMed ID: 11001387 [TBL] [Abstract][Full Text] [Related]
4. Secreted and tumour targeted human carboxylesterase for activation of irinotecan. Oosterhoff D; Pinedo HM; van der Meulen IH; de Graaf M; Sone T; Kruyt FA; van Beusechem VW; Haisma HJ; Gerritsen WR Br J Cancer; 2002 Sep; 87(6):659-64. PubMed ID: 12237777 [TBL] [Abstract][Full Text] [Related]
5. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin). Nagai S; Yamauchi M; Andoh T; Nishizawa M; Satta T; Kodera Y; Kondou K; Akiyama S; Ito K; Takagi H J Surg Oncol; 1995 Jun; 59(2):116-24. PubMed ID: 7776652 [TBL] [Abstract][Full Text] [Related]
6. Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Oliver PG; LoBuglio AF; Zinn KR; Kim H; Nan L; Zhou T; Wang W; Buchsbaum DJ Clin Cancer Res; 2008 Apr; 14(7):2180-9. PubMed ID: 18381960 [TBL] [Abstract][Full Text] [Related]
7. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues. Guichard S; Terret C; Hennebelle I; Lochon I; Chevreau P; Frétigny E; Selves J; Chatelut E; Bugat R; Canal P Br J Cancer; 1999 May; 80(3-4):364-70. PubMed ID: 10408839 [TBL] [Abstract][Full Text] [Related]
8. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913 [TBL] [Abstract][Full Text] [Related]
9. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Jansen WJ; Kolfschoten GM; Erkelens CA; Van Ark-Otte J; Pinedo HM; Boven E Int J Cancer; 1997 Dec; 73(6):891-6. PubMed ID: 9399672 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. Yano H; Kayukawa S; Iida S; Nakagawa C; Oguri T; Sanda T; Ding J; Mori F; Ito A; Ri M; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Inagaki H; Suzuki A; Ueda R Cancer Sci; 2008 Nov; 99(11):2309-14. PubMed ID: 18771527 [TBL] [Abstract][Full Text] [Related]
11. Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis. Sanghani SP; Quinney SK; Fredenburg TB; Sun Z; Davis WI; Murry DJ; Cummings OW; Seitz DE; Bosron WF Clin Cancer Res; 2003 Oct; 9(13):4983-91. PubMed ID: 14581373 [TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice. Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608 [TBL] [Abstract][Full Text] [Related]
13. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer. Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782 [TBL] [Abstract][Full Text] [Related]
14. New highly lipophilic camptothecin BNP1350 is an effective drug in experimental human cancer. Van Hattum AH; Pinedo HM; Schlüper HM; Hausheer FH; Boven E Int J Cancer; 2000 Oct; 88(2):260-6. PubMed ID: 11004678 [TBL] [Abstract][Full Text] [Related]
15. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11. Takeda S; Shimazoe T; Kuga H; Sato K; Kono A Biochem Biophys Res Commun; 1992 Oct; 188(1):70-7. PubMed ID: 1329748 [TBL] [Abstract][Full Text] [Related]
16. CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein. Jansen WJ; Hulscher TM; van Ark-Otte J; Giaccone G; Pinedo HM; Boven E Br J Cancer; 1998; 77(3):359-65. PubMed ID: 9472629 [TBL] [Abstract][Full Text] [Related]
17. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA. Kojima A; Hackett NR; Crystal RG Cancer Res; 1998 Oct; 58(19):4368-74. PubMed ID: 9766666 [TBL] [Abstract][Full Text] [Related]
18. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229 [TBL] [Abstract][Full Text] [Related]
19. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy. Prijovich ZM; Chen KC; Roffler SR Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567 [TBL] [Abstract][Full Text] [Related]
20. Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions. Philippart P; Harper L; Chaboteaux C; Decaestecker C; Bronckart Y; Gordover L; Lesueur-Ginot L; Malonne H; Lavergne O; Bigg DC; da Costa PM; Kiss R Clin Cancer Res; 2000 Apr; 6(4):1557-62. PubMed ID: 10778989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]